VivoSeq
Cardiovascular

High Cardiovascular Risk

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

High Cardiovascular Risk is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Mario Negri Institute for Pharmacological Research, Amgen.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalMario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

PreclinicalAmgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed10 · 83%
Unknown status1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
Not yet recruiting·XXiangya Hospital of Central South University·Phase 4·NCT06663254·410 enrolled
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Completed·—·Phase 3·NCT01154036·1,547 enrolled
Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Completed·MMedical University of Graz·Phase 4·NCT00814723·90 enrolled
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Completed·Novartis logoNovartis·Phase 2·NCT04666298·312 enrolled
SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
Completed·—·Phase 3·NCT03151343·92 enrolled
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Completed·GGWT-TUD GmbH·Phase 3·NCT02164578·179 enrolled
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
Completed·—·Phase 3·NCT00479713·618 enrolled
Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 3·NCT00317707·12,513 enrolled
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Completed·Amgen logoAmgen·Phase 3·NCT02207634·1,974 enrolled
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
Completed·HHippocration General Hospital·Phase 4·NCT01013103·72 enrolled
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
Completed·GGWT-TUD GmbH·N/A·NCT03110432·1,695 enrolled
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk
Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT04258371·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)